A comprehensive view of Moderna Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Transformation & Innovation Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA delays review of Moderna's RSV vaccine mRNA-1345 due to administrative constraints; review expected by end of May 2024
Published: May 10, 2024 by Moderna Inc.
Moderna Inc. - First Quarter 2024 Transcript
Published: May 02, 2024 by U.S. Markets (Alternative Disclosure) via PUBT
Metagenomi regains full rights to gene editing technologies following ‘mutual’ termination of development partnership with Moderna; the decision did not result from data issues
Published: May 02, 2024 by BioPharma Dive
Moderna outlines plans for cancer vaccine during Q1 earnings update, with three new Phase 2 studies for neoantigen cancer treatment mRNA-4157 under way; Moderna reports it will not continue to pursue its checkpoint inhibitor, a preclinical PD-L1 therapy
Published: May 02, 2024 by FierceBiotech
Moderna's Q1 revenue falls 91% as COVID-19 vaccine sales plunge; company anticipates resurgence with upcoming rollout of respiratory syncytial virus vaccine, with Fall 2024 targeted for launch
Published: May 02, 2024 by Quartz

Ask us about our Transformation & Innovation market view

Trending Chart

Interactive chart with headline count